The Trump administration could begin zeroing in on Medicare Part B spending next year, according to a FierceHealthcare report.
Bernstein analysts reportedly said recent spending data released by the Centers for Medicare and Medicaid Services, along with comments coming out of the agency, point to more concentrated focus on Part B.
Data released by CMS show retail drug costs rose only 0.4 percent last year, hitting $333 billion. The Medicare Payment Advisory Commission, however, said the main driver of outpatient spending growth was Part D drugs, rising 8.4 percent per beneficiary from 2016-17.
